

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO. PF3513USW	SERIAL NO. To be assigned
APPLICANT KNICK et al.			
FILING DATE Concurrently herewith		GROUP	

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page \_\_\_\_\_

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
SSM 1. EP 0252741 A	01/13/1988	EPO			

Continue on page \_\_\_\_\_

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

SSM 2.	Bleiberg, "Continuing the fight against advanced colorectal cancer: new and future treatment options," <i>Anti-Cancer Drugs</i> 9:1 18-28 (January 1998).
SSM 3.	Bokemeyer et al., "Current aspects of adjuvant and palliative chemotherapy in colorectal carcinoma! Aktuelle Aspekte zur adjuvanten und palliativen Chemotherapie beim kolorektalen Karzinom," <i>Schweizerische Rundschau Fur Medizin Praxis</i> 86:39 1510-1516 (September 1997).
SSM 4.	Casillas et al., "Adjuvant therapy for colorectal cancer: present and future perspectives," <i>Diseases of the Colon and Rectum</i> 40:8 977-992 (August 1997).
SSM 5.	Elias et al., "Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma," <i>American Journal of Respiratory and Critical Care Medicine</i> 15:4 1114-1122 (October 1994).
SSM 6.	Haisma et al., "A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer," <i>British Journal of Cancer</i> 66:3 474-478 (September 1992).
SSM 7.	Kievit et al., "Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer," <i>International Journal of Cancer</i> 71:2 237-245 (April 1997).
SSM 8.	Paul et al., "Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM)," <i>Hybridoma</i> 5 Suppl:1 S171-S174 (July 1986).
SSM 9.	Schwartzberg, "Chemotherapy plus PANOREX (17-1A monoclonal antibody) as adjuvant therapy for colon cancer: Ongoing studies," <i>Cancer Investigation</i> 17 Suppl:1 32-34 (1999).

Continue on page \_\_\_\_\_

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449  
INFORMATIONAL DISCLOSURE STATEMENT

ATTORNEY DOCKET NO. PU3513USw  
APPLICANT KNICK et al.  
FILING DATE January 18, 2002  
SERIAL NO. 10/031,355  
GROUP 1645

Page 1 of 2  
MAR 24 2003  
TECH CENTER 1 800 235 0000  
RECEIVED

MAR 20 2003  
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
SJM	1. WO 87/00462	01-1987	PCT			X (Abstract)
SJM	2. WO 92/07075	4-1992	PCT			

Continue on page



OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

SJM	3.	Bebbington et al., "High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker," <i>Bio/Technology</i> 10:169-175 (Feb. 1992).
SJM	4.	Bhuyan et al., "Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells," <i>Cancer Research</i> 52(2):5687-5692 (Oct. 1992).
SJM	5.	Chen et al., "Differences in inhibition of chromosome separation and G <sub>2</sub> arrest by DNA topoisomerase II inhibitors merbarone and VM-26," <i>Cancer Research</i> 55(7):1509-1516 (Apr. 1995).
SJM	6.	Colcher et al., "A spectrum of monoclonal antibodies reactive human mammary tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> 78(5):3199-3203 (May 1981).
SJM	7.	Czuczman et al., "IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells," <i>Cancer Immunology, Immunotherapy</i> 36(6):387-396 (1993).
SJM	8.	Ellis et al., "Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma," <i>The Journal of Immunology</i> 155:925-937 (1995).
SJM	9.	Engelholm et al., "Effect of Melphalan on growth curves and cell cycle distribution of four human small cell carcinomas of the lung grown in nude mice," <i>Experimental Cell Biology</i> 54(3):138-148 (1986).
SJM	10.	Erba et al., "Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line," <i>International Journal of Cancer</i> 62(2):170-175 (Jul. 1995).
SJM	11.	Fargion et al., "Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies," <i>Cancer Research</i> 46:2633-2638 (May 1986).
SJM	12.	Fogler et al., "Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen," <i>Cancer Research</i> 48:6303-6308 (1988).
SJM	13.	Greiner et al., "Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte $\alpha$ -interferon treatment," <i>Cancer Research</i> 44:3208-3214 (Aug. 1984).
SJM	14.	Greiner et al., "Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells," <i>J. Clin Oncol</i> 10(5):735-746 (May 1992).
SJM	15.	Herlyn et al., "CO 17-1A and related monoclonal antibodies: their production and characterization," <i>Hybridoma</i> 5(Suppl. 1):S3-S10 (1986).
SJM	16.	Herlyn et al., "Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 76(3):1438-1452 (Mar. 1979).
SJM	17.	Inaba et al., "Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells," <i>Oncology Research</i> 6(7):303-309 (1994).
SJM	18.	Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> 321:522 (May 1986).

Continue on page 2

EXAMINER *Alu* DATE CONSIDERED 9/9/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY/AGENT NO. PU3513USw		SERIAL NO. 10/031,355	
				APPLICANT KNICK et al.		FILING DATE January 18, 2002	
				GROUP 1645			
U.S. PATENT DOCUMENTS							
Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date Approximate	
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
	Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No	
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
SSH	19.	Kallio et al., "Effects of the DNA topoisomerase II inhibitor merbarone in male mouse meiotic divisions in vivo: Cell cycle arrest and induction of aneuploidy," <i>Environmental &amp; Molecular Mutagenesis</i> 29(1):16-27 (1997).					
SSH	20.	Klucar et al., "G2 cell cycle arrest and apoptosis are induced in Burkitt's lymphoma cells by the anticancer agent oracin," <i>FEBS Letters</i> 400(1):127-130 (Jan. 1997).					
SH	21.	Laio et al., "Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas," <i>Human Antibody Hybridomas</i> 1(2):66-76 (1990).					
SSH	22.	Litvinow et al., "Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule," <i>J. Cell Biology</i> 125:437-446 (1994).					
SSH	23.	Okabe et al., "Monoclonal antibodies to surface antigens of small cell carcinoma of the lung," <i>Cancer Research</i> 44:5273-5278 (Nov. 1984).					
SSH	24.	Reichmann et al., "Reshaping human antibodies for therapy," <i>Nature</i> 332:323-327 (Mar. 1988).					
SSH	25.	Riethmuller et al., "Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers," <i>Curr. Opin. Immun.</i> 4:647-655 (1992).					
SSH	26.	Riethmuller et al., "Monoclonal antibodies in cancer therapy," <i>Curr. Opin. Immun.</i> 5:732-739 (1993).					
SSH	27.	Rojas et al., "Genotoxic effects of bistratene A on human lymphocytes," <i>Mutation Research</i> 367(3):169-175 (Mar. 1996).					
	28.	Song, "Expression of sarcoma-associated antigens p102 and p200 in human sarcoma cell lines," <i>Anticancer Research</i> 16(3A):1171-1175 (1996).					
	29.	Stephens et al., "The construction of a highly efficient and versatile set of mammalian expression vectors," <i>Nucleic Acid Res.</i> 17(17):7110 (1989).					
	30.	Tyle, "Iontophoretic devices for drug delivery," <i>Pharmaceutical Research</i> 3(6):318-326 (1986).					
	31.	Verhoeyen et al., "Reshaping human antibodies: grafting an antilysozyme activity," <i>Science</i> 239:1534-1536 (Mar. 1988).					
	32.	Watters et al., "Accumulation of HL-60 leukemia cells in G2/M and inhibition of cytokinesis caused by two marine compounds, bistratene A and cyclozoline," <i>Cancer Chemotherapy &amp; Pharmacology</i> 33(5):399-409 (1994).					
	33.	Wei et al., "Expression of the surface antigen in human gastric cancer cells and the relation to cell cycles," <i>J of Oncology</i> 9(3):179-182 (1987) (Abstract).					
	34.	Wulf et al., "A cell-surface epitope associated with liver-preferential metastasis detected by the new monoclonal antibody 3H4 in the murine tumor model ER 15-P," <i>J Cancer Research and Clinical Oncology</i> 122(8):476-482 (1996).					
Continue on page _____							
EXAMINER 				DATE CONSIDERED 9/9/04			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

RECEIVED

TECH CENTER 1 MAR 24 2003